Abstract: AIM: To study the effect of inhalation of budesonide suspension and compound ipratropium bromide solution with oxygen driven nebulizers on arterial blood gas analysis and lung function of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and respiratory failure type II and to observe the side effects.METHODS: Thirty AECOPD hospitalization patients were selected in the study, each one inhaled 2 mL budesonide suspension and 2.5 mL compound ipratropium bromide solution with oxygen driven nebulizers (oxygen flow 5 L min) for about 20minutes.Arterial blood gas and peak expiratory flow (PEF) were measured before inhalation of budesonide suspension and compound ipratropium bromide solution and half an hour after inhalation finished, at the same time, the percutaneous oxygen saturation, consciousness, breathing, heart rate were monitored.RESULTS: The inhalation of budesonide suspension and compound ipratropium bromide solution led to the increase in PaO² and PEF, a decrease in PaCO². There were significantly positive correlations between the improvement rate of PEF and the decrease of PaCO².The side effects were tolerable.CONCLUSION: Inhalation of budesonide suspension and compound ipratropium bromide solution with oxygen driven nebulizers could treat the patients with AECOPD and respiratory failure type II with hypoxia and hypercapnia by improving their lung function.The usage of oxygen driven nebulizers has good efficacy and safety for the patients with AECOPD and respiratory failure type II.

Key words: chronic obstructive pulmonary disease, respiratory failure type II, oxygen driven nebulizers, budesonide suspension, compound ipratropium bromide solution